Vés al contingut

A phase 2/3, randomized, open-label, parallel group, 2-arm, multicenter study investigating the efficacy and safety of intravenous administrations of anakinra, an interleukin-1(IL-1) receptor antagonist, added to standard of care, versus standard of care, in reducing hyper-inflammation and respiratory distress in patients with SARS- CoV-2 infection.

Obert
  • Codi protocol: ANA-COVID-GEAS
  • Codi EudraCT: 2020-001825-29
  • Grup de recerca: Malalties Sistèmiques
  • Servei: Medicina Interna
  • Investigador/a principal:  Bujan Rivas, Segundo
  • Malaltia: Certes malalties infeccioses i parasitàries
  • Fase: Fase III
  • Estat reclutament: Reclutant voluntaris